5,6,7,9-tetrahydro-7-hydroxy-9-oxoimidazo(1,2-a)purine: derivative of N(2)-(2-oxoethyl)guanine; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 127814 |
MeSH ID | M0226960 |
Synonym |
---|
5,6,7,9-thop |
1,5,6,7-tetrahydro-7-hydroxy-9h-imidazo(1,2-a)purin-9-one |
5,6,7,9-tetrahydro-7-hydroxy-9-oxoimidazo(1,2-a)purine |
9h-imidazo(1,2-a)purin-9-one, 1,5,6,7-tetrahydro-7-hydroxy- |
151900-35-5 |
7-hydroxy-1,5,6,7-tetrahydroimidazo[1,2-a]purin-9-one |
5,6,7,9-tetrahydro-7-hydroxy-9-oxoimidazo[1,2-a]purine |
7-hydroxy-3,4,6,7-tetrahydro-9h-imidazo[1,2-a]purin-9-one |
DTXSID90934365 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |